Ligand Pharmaceuticals (LGND) investor relations material

Executive summary

• Achieved strong financial performance in 2025, with full-year adjusted EPS up 42% to $8.13, exceeding original guidance by over 30%, and royalty revenue growing 48% year-over-year, driven by key products including FILSPARI, Ohtuvayre, CAPVAXIVE, QARZIBA, and Zelsuvmi.

• Strategic initiatives included systematic portfolio management, expansion of the business development team, and special transactions such as the Pelthos and Channel Therapeutics merger.

• Portfolio includes 12 key commercial royalty assets generating ~$200M in cash flow and a deep pipeline supporting future growth.

• Maintained over $1 billion in deployable capital, positioning for continued expansion and disciplined investments.

Financial highlights

• Full-year 2025 GAAP revenue reached $268 million, up from $167 million in 2024; core revenue (excluding Pelthos gain) was $240 million, up 43% year-over-year.

• Royalty revenue grew to $161 million, a 48% increase year-over-year; Q4 total revenue was $59.7 million, up 39% from the prior year.

• Core adjusted diluted EPS rose to $8.13, up 42% year-over-year; Q4 adjusted net income was $42.7 million or $2.02 per share.

• Ended 2025 with $734 million in cash equivalents and short-term investments, and over $1 billion in deployable capital including equity holdings and credit facility.

• Operating income improved to $41 million from a loss of $22.6 million in 2024.

Outlook and guidance

• 2026 guidance reaffirmed: adjusted EPS of $8–$9 per share, royalty revenue of $200–$225 million (32% growth at midpoint), total revenue of $245–$285 million.

• Royalty growth in 2026 expected to be driven by FILSPARI, Ohtuvayre, CAPVAXIVE, and ZELSUVMI.

• Five-year outlook projects a 23% CAGR in royalty receipts from 2025–2030, with visibility to over $13.50 adjusted EPS by 2030.